// App-Quantinova.ai

279 : Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA

Researchers

Presenter

  • Alejandro Balsa

Principal Investigators

  • Siegfried Wassenberg

  • Anne Tournadre

  • Hans-Dieter Orzechowski

  • Katrien Van Beneden

  • Vijay Rajendran

  • Udo Lendl

  • Pieter-Jan Stiers

  • Christopher Watson

  • Roberto Felice Caporali

  • Patrick Verschueren

Medical Centers

  • Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

  • Rheuma Zentrum Ratingen, Ratingen, Germany

  • University Hospital Clermont-Ferrand, Clermont-Ferrand, France

  • Galapagos Biopharma Deutschland GmbH, Munich, Germany

  • Galapagos, Mechelen, Belgium

  • Galapagos NV, Gent, Belgium

  • Galapagos Biotech Ltd, Cambridge, United Kingdom

  • University of Milan, Milan, Italy

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

Locations

  • Spain

  • Germany

  • France

  • Belgium

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Complement Factor B

  • Body mass index

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02889796

  • NCT02873936

  • NCT02886728

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved